Tolmar, Inc., a specialty pharmaceutical company, has officially opened its new Northern Illinois Laboratory at Rosalind Franklin University’s Innovation and Research Park (IRP) in North Chicago, Illinois. This facility enhances Tolmar’s capabilities in developing and commercializing pharmaceutical products, while contributing to the university’s growing ecosystem of industry innovation.
Founded in 2007, Tolmar is recognized for its advanced long-acting injectable drug delivery technologies, focusing on specialized pharmaceuticals in fields such as urology, oncology, and endocrinology. Its flagship product, which treats advanced prostate cancer, is marketed in 89 countries worldwide.
The establishment of the new research facility at Rosalind Franklin University aims to complement the experienced teams based in Colorado. This strategic move not only strengthens Tolmar’s regional presence but also integrates its executive offices and sales and marketing operations located in Buffalo Grove, Illinois.
Dr. Dave Loffredo, Vice President of Innovation at Tolmar, expressed enthusiasm regarding the new laboratory, stating, “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois. After an exhaustive search, we found a great home at Rosalind Franklin’s IRP.” He emphasized the eagerness of Tolmar scientists to engage with the vibrant research environment at the university.
The laboratory is positioned within a state-of-the-art, 100,000-square-foot facility that houses six research centers at RFU, including the Center for Cancer Cell Biology, Immunology, and Infection. Dr. Stace Porter, Senior Vice President of Development Operations for Tolmar, highlighted the advantages of this new location: “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores.”
Rosalind Franklin University is known for its research contributions across various fields, including neuroscience, brain-related diseases, and inherited disorders. Dr. Joseph DiMario, Executive Vice President for Research at RFU, welcomed Tolmar to the university’s community, stating, “We look forward to collaborations that can help accelerate new product development. The IRP provides an environment that fosters the kind of intellectual biomedical “collisions” that drive meaningful innovation.”
Tolmar’s expansion into the IRP aligns with its mission to innovate in specialty pharmaceuticals, reinforcing its commitment to improving patient outcomes in critical therapeutic areas. The collaboration with Rosalind Franklin University is expected to yield significant advancements in pharmaceutical research and development, benefiting both organizations and the broader healthcare landscape.
For more information about Tolmar, visit their website at www.tolmar.com. To learn more about Rosalind Franklin University, go to rosalindfranklin.edu.
